My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Farmacia Hospitalaria
On-line version ISSN 2171-8695Print version ISSN 1130-6343
Abstract
SAMPEDRO-GIMENO, Teresa et al. Observational real world data with palbociclib associated to hormone therapy for advanced breast carcinoma. Farm Hosp. [online]. 2021, vol.45, n.6, pp.329-334. Epub Dec 19, 2022. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.11695.
Objective:
Cyclin-dependent kinase 4/6 inhibitors have a synergistic effect in combination with endocrine therapy. This combination is used as first and subsequent-line treatment for advanced luminal breast carcinoma because it increases progression-free survival. We analysed clinical course and toxicity in patients treated with palbociclib in our hospital and determined potential associations between these variables and clinicopathological variables.
Method:
Observational retrospective study including patients with advanced or metastatic breast cancer treated with palbociclib plus endocrine therapy at the Hospital Universitario de Cabueñes between 2017 and 2020. We analysed clinicopathological variables, toxicity, and survival.
Results:
In total, 72 women and 1 man (median age: 63 years) received palbociclib plus an aromatase inhibitor or fulvestrant. When used as firstline treatment, progression-free survival was 22 months, and as second and subsequent-line treatment, progression-free survival was 13 months. Adverse effects (mainly haematological) were experienced by nearly all patients (95.9%). Treatment was not discontinued because of toxicity in any patient, although delays and dose adjustments were common (61.7% and 42.7%, respectively). Performance status alone had a significant impact on progression-free survival (22 months in patients with ECOG 0 vs 12 months in patients with ECOG ≥ 1; P = 0.021).
Conclusions:
Disease stage, age, and performance status do not limit the use of treatment with palbociclib, nor its combination with aromatase inhibitors or fulvestrant for first or subsequent-line treatment. Toxicity is easily managed. Real-world results are equivalent to those published to date.
Keywords : Breast cancer; Cyclin-dependent kinase inhibitor proteins; Palbociclib; Aromatase inhibitors; Fulvestrant; Drug-related side effects and adverse reactions; Progression-free survival.